Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernández-Rivas JÁ, Hong X, Kim SJ, Lewis D, Mishima Y, Özcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, Dreyling M; SHINE Investigators. Wang ML, et al. Among authors: perini gf. N Engl J Med. 2022 Jun 30;386(26):2482-2494. doi: 10.1056/NEJMoa2201817. Epub 2022 Jun 3. N Engl J Med. 2022. PMID: 35657079 Clinical Trial.
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, Fogliatto LM, Goncalves I, de Oliveira JSR, Buccheri V, Perini GF, Goldschmidt N, Kriachok I, Dickinson M, Komarnicki M, McDonald A, Ozcan M, Sekiguchi N, Zhu Y, Nahar A, Marinello P, Zinzani PL; KEYNOTE-204 investigators. Kuruvilla J, et al. Among authors: perini gf. Lancet Oncol. 2021 Apr;22(4):512-524. doi: 10.1016/S1470-2045(21)00005-X. Epub 2021 Mar 12. Lancet Oncol. 2021. PMID: 33721562 Clinical Trial.
Editorial: Advances in the treatment of Hodgkin lymphoma.
Mei M, Perini G, Ramchandren R. Mei M, et al. Front Oncol. 2023 Feb 28;13:1164081. doi: 10.3389/fonc.2023.1164081. eCollection 2023. Front Oncol. 2023. PMID: 36925934 Free PMC article. No abstract available.
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170.
Zinzani PL, Thieblemont C, Melnichenko V, Bouabdallah K, Walewski J, Majlis A, Fogliatto L, Garcia-Sancho AM, Christian B, Gulbas Z, Özcan M, Perini GF, Ghesquieres H, Shipp MA, Thompson S, Chakraborty S, Marinello P, Armand P. Zinzani PL, et al. Among authors: perini gf. Blood. 2023 Jul 13;142(2):141-145. doi: 10.1182/blood.2022019340. Blood. 2023. PMID: 37130017 Free PMC article. Clinical Trial.
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.
Mato AR, Roeker LE, Jacobs R, Hill BT, Lamanna N, Brander D, Shadman M, Ujjani CS, Yazdy MS, Perini GF, Pinilla-Ibarz JA, Barrientos J, Skarbnik AP, Torka P, Pu JJ, Pagel JM, Gohil S, Fakhri B, Choi M, Coombs CC, Rhodes J, Barr PM, Portell CA, Parry H, Garcia CA, Whitaker KJ, Winter AM, Sitlinger A, Khajavian S, Grajales-Cruz AF, Isaac KM, Shah P, Akhtar OS, Pocock R, Lam K, Voorhees TJ, Schuster SJ, Rodgers TD, Fox CP, Martinez-Calle N, Munir T, Bhavsar EB, Bailey N, Lee JC, Weissbrot HB, Nabhan C, Goodfriend JM, King AC, Zelenetz AD, Dorsey C, Bigelow K, Cheson BD, Allan JN, Eyre TA. Mato AR, et al. Among authors: perini gf. Clin Cancer Res. 2020 Jul 15;26(14):3589-3596. doi: 10.1158/1078-0432.CCR-19-3815. Epub 2020 Mar 20. Clin Cancer Res. 2020. PMID: 32198151 Free PMC article.
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
Roeker LE, Eyre TA, Thompson MC, Lamanna N, Coltoff AR, Davids MS, Baker PO, Leslie L, Rogers KA, Allan JN, Cordoba R, Lopez-Garcia A, Antic D, Pagel JM, Martinez-Calle N, García-Marco JA, Hernández-Rivas JÁ, Miras F, Coombs CC, Österborg A, Hansson L, Seddon AN, López Jiménez J, Wilson MR, El-Sharkawi D, Wojenski D, Ma S, Munir T, Valenciano S, Seymour E, Barr PM, Pu J, Patten PEM, Perini GF, Huntington SF, Parry H, Sundaram S, Skarbnik A, Kamdar M, Jacobs R, Walter H, Walewska R, Broom A, Lebowitz S, Isaac KM, Portell CA, Ahn IE, Ujjani CS, Shadman M, Skånland SS, Chong EA, Mato AR. Roeker LE, et al. Among authors: perini gf. Blood. 2021 Nov 4;138(18):1768-1773. doi: 10.1182/blood.2021011841. Blood. 2021. PMID: 34297826 Free PMC article. No abstract available.
Brentuximab vedotin in Hodgkin's lymphoma.
Pro B, Perini GF. Pro B, et al. Among authors: perini gf. Expert Opin Biol Ther. 2012 Oct;12(10):1415-21. doi: 10.1517/14712598.2012.718328. Epub 2012 Aug 31. Expert Opin Biol Ther. 2012. PMID: 22937794 Review.
Brentuximab Vedotin in CD30+ Lymphomas.
Perini GF, Pro B. Perini GF, et al. Biol Ther. 2013;3(1):15-23. doi: 10.1007/s13554-013-0008-7. Epub 2013 Mar 1. Biol Ther. 2013. PMID: 24392301 Free PMC article. Review.
37 results